Latest Content

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

February 20th 2025, 2:00pm

By Jax DiEugenio

Article

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

February 19th 2025, 10:00pm

By Jax DiEugenio

Article

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

February 19th 2025, 8:00pm

By Ryan Scott

Article

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.

Navigating Time and Emotions After Testicular Cancer

February 19th 2025, 6:00pm

By Brian Sluga

Article

I often reflect on my emotional changes following a testicular cancer diagnosis and how I learned to manage them and grow.

Explaining PROs From the TiNivo-2 Study in Advanced Renal Cell Carcinoma

February 19th 2025, 5:00pm

By Dr. Katy Beckermann

Video

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.

What Patients With Cancer Need to Know About Counterfeit Drugs Risk

February 19th 2025, 4:00pm

By Alex Biese

Article

It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

SBRT May Be Superior to Radiofrequency Ablation in Liver Cancer

February 19th 2025, 2:00pm

By Spencer Feldman

Article

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

February 18th 2025, 10:00pm

By Ashling Wahner

Article

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

Cancer Vaccine Elicits Promising Responses in Renal Cell Carcinoma

February 18th 2025, 8:00pm

By Alex Biese

Article

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

The Good and The Bad of Follicular Lymphoma

February 18th 2025, 6:00pm

By Karen Cohn

Article

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring monitoring and follow-up.

An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment

February 18th 2025, 5:00pm

By Dr. Petros Grivas

Video

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.

The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma

February 18th 2025, 4:00pm

By Ryan Scott

Article

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.

Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

February 18th 2025, 2:00pm

By Kristi Rosa

Article

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer

February 17th 2025, 10:00pm

By Dr. Debu Tripathy

Video

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC

February 17th 2025, 8:00pm

By Kristi Rosa

Article

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.